Introduction
Apoptosis is a complex regulatory process that involves changes in the expression of several genes. Deregulation of apoptosis is one of the hallmarks of cancer and can contribute to uncontrollable proliferation and tumor growth. Apoptosis can be mediated either by the death-receptor pathway [1] or by the mitochondrial pathway [2] .
The mitochondrial-mediated pathway is controlled by the Bcl-2 family of proteins and involves the alteration of mitochondrial membrane permeability and the release of apoptotic proteins, such as cytochrome c, from the mitochondria to cytosol. Cytochrome c together with apoptosis protease-activating factor-1 (Apaf-1) work in coordination with caspase-9 to activate caspase-3 [3] . The death receptor-mediated pathway is initiated by the ligation of cell death ligands, such as tumor necrosis factor (TNF) and TNF-related apoptosis-inducing ligand (TRAIL), with their death receptors. Ligation first triggers activation of the initiator caspase-8 and finally the effector caspase-3. Both pathways ultimately lead to the activation of caspase 3, which executes the apoptotic processes resulting in cell death [3, 4] .
Compounds that can induce apoptosis in tumor cells are important tools in cancer research and are sought as possible anticancer agents. Morphine, the exogenous ligand of the μ-opioid receptor (MOR), is one of the most effective drugs available clinically for the management of severe pain associated with cancer. In addition to its use in the treatment of pain, morphine appears to be important in the regulation of neoplastic tissue. Therefore, understanding the impact of morphine on cancer treatment is extremely important. Accumulating evidence suggests that morphine can affect proliferation, apoptosis and the migration of tumor cells. However, the effect of morphine on tumor growth is still contradictory, as both growth promoting and growth inhibiting effects have been observed [5] .
In the present study, we investigated the influence of morphiceptin, a MOR-selective peptide, and its two very potent synthetic analogs (Figure 1 ), on apoptosis in cancer cells. The following cell lines were examined: breast MCF-7, colon HT-29 adenocarcinomas, and neuroblastoma SH-SY5Y. These lines have been previously reported to shown high levels of MOR [6] . 3 ] morphiceptin, were synthesized in our laboratory using a standard solid-phase method as previously described [7] .
Experimental Procedures

Cell cultures
The MCF-7 human breast adenocarcinoma, SH-SY5Y neuroblastoma and HT-29 colon cancer cell lines were purchased from the European Collection of Cell Cultures (ECACC). All cell lines were cultured according to protocols provided by the manufacturer. Culture mediums were supplemented with gentamycin (5 μg/ml) and 10% heat inactivated fetal bovine serum (both from Biological Industries, Haemek, Israel). Cells were maintained at 37°C in a 5% CO 2 atmosphere and grown until they were 80% confluent.
Incubation with opioids
Cells (MCF-7, SH-SY5Y, HT-29) were seeded in 25 mL cell culture flasks in 10 mL of standard growth medium. After 24 h, the growth medium was replaced by fresh medium supplemented with the opioid compound of interest in the desired concentration. Cells incubated without the addition of an opioid compound were used as control. After incubation, cells were washed twice with phosphate buffered saline (PBS, GIBCO, Invitrogen, Carlsbad, CA, USA) to remove added compounds and were then harvested by trypsinization. The cells were frozen then at -80°C prior to RNA isolation and protein analysis.
Quantitative real-time PCR assay
Total RNA was extracted from the MCF-7, HT-29 or SH-SY5Y cells using Total RNA Mini Kit (A&A Biotechnology, Poland) according to the manufacturer's protocol. The concentration and purity of isolated RNA was determined using a spectrophotometer to examine absorbance at 260 and 280 nm. cDNA was synthesized using the Enhanced Avian HS RT-PCR Kit and oligo(dT) [12] [13] [14] [15] [16] [17] [18] primers (Sigma-Aldrich, St. Louis, MO, USA). Caspase-3, Bax, and Bcl-2 transcripts were quantified by real-time PCR using the Mx3005P QPCR System (Agilent Technologies, Inc. Santa Clara, CA, USA) according to the manufacturer's protocol for the Brilliant II SYBR Green QPCR Master Mix (Agilent Technologies, Inc. Santa Clara, CA, USA). The housekeeping gene, glyceraldehydes 3-phosphate dehydrogenase (GAPDH), was selected as the internal control. cDNAs were amplified with forward and reverse primers that were specific for human caspase-3, Bax, Bcl-2, and GAPDH transcripts. Caspase-3 primer sequences were 5'-TGAAGCTACCTCAAACTTCC-3' (forward) and 5'-CAGCATCACTGTAACTTGCT-3' (reverse). Bax primer sequences were 5'-ACCCGGTGCCTCAGGATGCGT-3' (forward) and 5'-GGCAAAGTAGAAAAGGGCGAC-3' (reverse). Bcl-2 primer sequences were 5'-CATGCTGGGGCCGTACAG-3' (forward) and 5'-GAACCGGCACCTGCACAC-3' (reverse). GAPDH primer sequences were 5′-GTCGCTGTTGAAGTCAGAGGAG-3′ (forward) and 5′-CGTGTCAGTGGTGGACCTGAC-3′ (reverse).
Real-time PCR reactions were run in triplicate using the following thermal cycling profile: 95°C for 10 min, followed by 40 cycles of 95°C for 30 s and 58°C for 1 min and 72°C for 1 min. After 40 cycles, a standard dissociation protocol was applied to samples (i.e. melting curve analysis). Brilliant II SYBR Green fluorescence emissions were captured and mRNA levels were quantified using the critical threshold (Ct) value. A no-template control was included in each assay. Relative gene expression levels were determined using the ∆∆C t method [8] .
Protein determination
Cells collected after treatment with the test compounds were washed twice with phosphate buffered saline (PBS, GIBCO, Invitrogen, Carlsbad, CA, USA). Cell pellets were frozen at -80°C. Cells were then lysed and 
Analysis of apoptosis by flow cytometry
Apoptotic cell death was determined using the FITC Annexin V Apoptosis Detection Kit (BD Bioscience, NJ USA). Briefly, cells were treated for 48 h with test compounds at a concentration of 10 -7 M. The cells were harvested, washed with PBS, stained with annexin V and propidium iodide (PI) in the binding buffer and kept for 15 min at room temperature in the dark. Then flow cytometry analysis was performed (FACS Canto II, Becton). Early and late apoptosis was visualized and quantified by constructing a dot-plot using BD FACSDiva software.
Statistical analysis
Statistical analyses were performed using Prism 4.0 (GraphPad Software Inc., San Diego, CA, USA). The data were expressed as means ± SD. Differences between groups were assessed by a one-way ANOVA followed by a post-hoc multiple comparison StudentNewman-Keuls test. A probability level of 0.05 or lower was considered statistically significant.
Results
Effect of opioids on caspase-3, Bax and Bcl-2 gene expression
To investigate the effect of morphiceptin and analogs 1 and 2 on the induction of apoptosis in cancer cells, caspase-3, Bax and Bcl-2 mRNA expression levels were measured using quantitative real-time PCR. Concentration response (10 -9 to 10 -5 M) and time course experiments (12, 24, 48, 72 h) were first performed to choose the optimal conditions. The results for MCF-7 cells are given in Figure 2 (concentration-response) and in Figure 3 (time-course) . In case of all three cell lines the maximal effect was observed after 48 h incubation of peptides at a concentration of 10 -7 M. The results for the chosen concentration and incubation time are shown in Figure 4 . In all three tested cell lines, mRNA levels of the pro-apoptotic genes, caspase 3 and Bax, were significantly up-regulated, while down-regulation was observed for anti-apoptotic Bcl-2 mRNA level. Only small differences were found among analogs and among tested cell lines, which could suggest an opioid receptor-independent mechanism of action. To confirm this hypothesis, the opioid anatagonist, naloxone (10 -7 M) was included in the study. As shown in Figure 5 , naloxone did not reverse opioid induced changes in caspase-3, Bax and Bcl-2 mRNA levels.
Effect of opioids on caspase-3, Bax and Bcl-2 protein level
In addition to mRNA quantification, protein levels were investigated using an ELISA assay for the genes of interest. Data showed that opioid treatment influenced caspase-3, bax, bcl-2 protein levels, however the effects were slight and not reversible by treatment with naloxone (10 -7 M) ( Figure 6 ).
Analysis of apoptosis by flow cytometry
Annexin V/PI analysis was applied to quantify the apoptotic profile. In apoptotic cells, the membrane phospholipide, phosphatidylserine, is translocated from the inner to the outer portion of the membrane, and thus can be detected by annexin V-FITC, a phospholipid binding protein [9] . Meanwhile, the dead cells with disintegrated membranes can be detected by the binding of PI to their cellular DNA. The results of the annexin V/PI binding analysis by flow cytometry are shown in Figure 7A . The percentage of MCF-7 cells within the population undergoing apoptosis or necrosis are given in Table 1 . The total number of apoptotic cells (early and late apoptosis) was increased by 46%, 37% and 42% following treatment with morphiceptin, analog 1 and analog 2 respectively ( Figure 7B ). Differences between morphiceptin and its analogs were not found to be statistically significant. These results support our hypothesis that opioid induction of apoptosis is not mediated by opioid receptors. 
Discussion
The pharmacology and function of opioids in the central nervous system have been extensively characterized, yet little is known about their effect on cancer cells.
Apoptosis is usually deregulated in cancer cells and this deregulation can contribute to uncontrollable proliferation and tumor growth [3, 10, 11] . Morphine has been shown to induce apoptosis in many human cancer cells lines [12] [13] [14] . However not much is known about the influence of endogenous opioid peptides on apoptosis modulation. Results are often contradictory and significant differences often occur between cell lines. For example endomorphins, endogenous MOR A C B agonists, were found to induce apoptosis in human leukemia HL-60 cells [15] , but show no effect on cell survival in MIA PaCa-2 pancreatic adenocarcinoma, HT-29 colon adenocarcinoma, and CAL-27 oral adenosquamous carcinoma cell lines [16] . In our search for highly potent MOR-selective peptides as potential new analgesics, we have synthesized numerous analogs of MOR-selective agonists, endomorphin-2 and morphiceptin. Pharmacological studies of these analogs demonstrated that compounds with a higher affinity to MOR also had stronger antinociceptive activity.
In this study we wanted to examine whether opioid peptides (morphiceptin and its anqlogs with high MOR affinity) are able to induce apoptosis in cancer cells. One of the molecules responsible for maintaining the balance between cell proliferation and apoptosis is anti-apoptotic Bcl-2 protein [17] . This protein is localized on the outer mitochondrial membranes and antagonizes the action of pro-apoptotic Bax. The balance between these two proteins prevents translocation of cytochrome c from the mitochondria and determines apoptosis resistance. Inhibition of Bcl-2 or/and induction of Bax disrupts this balance [18, 19] . Cytochrome c binds to Apaf-1 in the cytosol leading to the activation of procaspase-9, whose stimulation activates caspase-3. which leads to the execution phase of cell apoptosis [20] .
We have found that morphiceptin and the two selected analogs each induced apoptosis in the three types of cancer cells tested. Apoptosis induction was associated with up-regulation of pro-apoptotic Bax protein and downregulation of anti-apoptotic Bcl-2 and with increased activity of executioner caspase 3. Flow cytometry results confirmed that the tested opioids induced apoptosis in cancer cells but only small differences were observed between the analogs. Moreover, the effect produced by opioids was not reversed by naloxone, indicating that in tested cancer cells, opioid peptides could induce apoptosis by mechanisms that were not mediated by opiod receptors. These results are consistent with previous findings obtained for morphine. Lin et al. [21] demonstrated that high-dose morphine treatment led to apoptotic cell death in SH-SY5Y cells. Moreover they showed that naloxone was not able to block morphineinduced apoptosis, suggesting that a typical opioid receptor-related mechanism was not involved in opioidinduced apoptosis of tumor cells. In another study, Tegeder et al. [22] observed that the anti-proliferative effects of morphine were not antagonized by naloxone, suggesting that the typical opioid receptor-coupled signaling cascade involving the G i , adenylyl cyclase, and protein kinase A was not involved. Instead, morphine treatment results in an N-terminal phosphorylation of p53 in MCF-7 cells. This p53 phosphorylation was not antagonized by naloxone and resulted in an increase of p53-dependent proteins, including Bax.
In conclusion, our results demonstrated that in cancer cells opioid peptides can induce apoptosis by mechanisms that are not mediated by the opiod receptors. Further research is necessary to provide clearer understanding of the influence of opioid peptides on apoptosis machinery. 
